Editas Medicine (EDIT) Cash from Financing Activities (2015 - 2025)

Editas Medicine (EDIT) has reported Cash from Financing Activities for 11 consecutive years, with $17.2 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Cash from Financing Activities changed N/A year-over-year to $17.2 million; the TTM figure through Sep 2025 stood at $78.7 million (up 7551.46% YoY), while the FY2024 annual figure was $56.0 million, down 52.54% from the prior year.
• Cash from Financing Activities rose to $17.2 million in Q3 2025 per EDIT's latest filing, from $7.4 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $261.5 million in Q1 2021 and bottomed at -$1.4 million in Q1 2025.
• Historically, Cash from Financing Activities has averaged $30.0 million across 5 years, with a median of $838000.0 in 2021.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 31923.16% — and 2025, when it tumbled 848.44%.
• Editas Medicine's Cash from Financing Activities stood at $1.1 million in 2021, then tumbled by 41.44% to $619000.0 in 2022, then decreased by 16.96% to $514000.0 in 2023, then surged by 10700.19% to $55.5 million in 2024, then slumped by 69.07% to $17.2 million in 2025.
• Business Quant data shows EDIT's Cash from Financing Activities at $17.2 million in Q3 2025, $7.4 million in Q2 2025, and -$1.4 million in Q1 2025.